Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07546760 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
A Phase 1 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT07546760 is a Phase 1 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 28 participants.
The verdict
NCT07546760, a Phase 1 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.
Interventions
- DRUG AZD6234
- DRUG AZD9550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-03-20 |
| Est. Completion | 2027-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07546760
The ClinicalTrials.gov registry entry for NCT07546760 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD6234 is the first listed.
NCT07546760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07546760 about?
NCT07546760 is a clinical study titled "A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234". The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.
What is the current status of trial NCT07546760?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2026-03-20. Estimated completion is 2027-02-04.
What interventions are being tested in trial NCT07546760?
The interventions under investigation include: AZD6234 (DRUG), AZD9550 (DRUG).
Who is sponsoring clinical trial NCT07546760?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.